Recordati Industria Chimica e Farmaceutica S.p.A. ADR (RICFY)

Overview

Recordati Industria Chimica e Farmaceutica S.p.A., a distinguished entity within the pharmaceutical sector, significantly contributes to the field through extensive research, development, manufacturing, and global marketing of pharmaceutical products. Established in 1926 and based in Milan, Italy, the company stands as a vital subsidiary of Rossini S.à R.L. Operating through Specialty and Primary Care, alongside Rare Diseases segments, Recordati is committed to delivering innovative healthcare solutions across various therapeutic areas. Its extensive international presence underscores its global outlook and commitment to improving patient care worldwide.

Products and Services

Recordati's portfolio encompasses a broad range of pharmaceutical products and medical devices, catering to both common and rare conditions:

• REC 0559: Currently in Phase II clinical trials, this product candidate aims to address Neurotrophic Keratitis, a rare degenerative disease of the cornea.
• REC 0545: This investigational drug is targeted at treating acute decompensation in individuals with maple syrup urine disease, a metabolic disorder affecting amino acid processing.
• ISTURISA: Approved for use in treating endogenous Cushing's syndrome, ISTURISA offers a significant therapeutic option for this hormonal disorder.
• CYSTADROPS: A specially formulated eye drop solution for the treatment of corneal cystine deposits in patients with cystinosis, showcasing Recordati’s expertise in rare disease management.
• CARBAGLU: This medication is designed for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency, a rare genetic disorder.
• QARZIBA: Focused on pediatric oncology, QARZIBA is used in the treatment of high-risk neuroblastoma patients who have either a partial response following chemotherapy, myeloablative therapy, and stem cell transplantation, or in cases of relapsed or refractory neuroblastoma.
• SYLVANT: SYLVANT addresses idiopathic multicentric Castleman’s disease, providing patients with a key option for this rare lymphoproliferative disorder.
• REAGILA: This treatment offers a novel approach for managing schizophrenia, contributing to the broader mental health therapeutic area.
• ELIGARD: Specifically developed for hormone-dependent prostate cancer, ELIGARD represents a vital treatment option within oncology.
• CAPHOSOL: A unique medical device, CAPHOSOL is indicated for the treatment of oral mucositis, a common side effect of cancer chemo and radiation therapy, demonstrating Recordati’s commitment to supportive care in oncology.